Richard Conklin, MD
Hematology & Oncology · Aberdeen, SDNPI 1851394662
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $908 of the $1,065 with a category attached, or 85.3%. It is spread thinly across 22 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations.
Across 41 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$124
- Alkermes, Inc.$109
- Sanofi$101
- E.r. Squibb & Sons, L.L.C.$101
- Pfizer$82
- Beigene USA, Inc.$73
- plus $475 from 16 others
Across 4 payments — averaging $3070.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$12K
What the payments were for
- Food & beverage$90885%
- Education$15715%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 5 | $124 |
| Alkermes, Inc. | 3 | $109 |
| Sanofi | 1 | $101 |
| E.r. Squibb & Sons, L.L.C. | 4 | $101 |
| Pfizer | 4 | $82 |
| Beigene USA, Inc. | 1 | $73 |
| Phathom Pharmaceuticals, Inc. | 1 | $65 |
| Novartis | 2 | $62 |
| Eisai Inc. | 3 | $53 |
| Myriad Genetic Laboratories, Inc. | 2 | $36 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Amgen | 2 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Merck | 1 | $26 |
| Gilead | 2 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Bristol Myers Squibb | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROSTATE CANCER - DISEASE$101
- JEVTANA$101
How this compares
$1,065 in reported general payments places this provider in the 60th percentile of 28 hematology & oncology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 45 | $695,485 |
| CabometyxCabozantinib S-Malate | 15 | $377,567 |
| VerzenioAbemaciclib | 19 | $256,040 |
| KisqaliRibociclib Succinate | 15 | $249,364 |
| CalquenceAcalabrutinib Maleate | 15 | $186,632 |
| InlytaAxitinib | 12 | $159,624 |
| BrukinsaZanubrutinib | 12 | $159,380 |
| ErleadaApalutamide | 12 | $157,637 |
| EliquisApixaban | 42 | $24,892 |
| Liothyronine Sodium | 150 | $4,497 |
| Anastrozole | 213 | $4,402 |
| Potassium Chloride | 119 | $4,203 |
| Anagrelide Hcl | 27 | $2,635 |
| Letrozole | 91 | $1,673 |
| Dexamethasone | 87 | $1,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $18 | $695,48545 claims |
| NovartisKisqali | $62 | $249,36415 claims |
| PfizerInlyta, Eliquis | $82 | $184,51654 claims |
| Beigene USA, Inc.Brukinsa | $73 | $159,38012 claims |
| Johnson & JohnsonErleada | $15 | $157,63712 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $15 | $1,213117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 hematology & oncology providers in South Dakota.
Other hematology & oncology in Aberdeen
- Kelly McCaulSioux Falls$1.2M
- Bipinkumar AminWatertown$292K
- Roberto Ferro ValdesSioux Falls$142K
- Vijay RaoWatertown$26K
- Waqas JehangirSioux Falls$23K
- Steven PowellSioux Falls$13K
- Benjamin SolomonSioux Falls$5K
- James KuzmanRapid City$2K
- Miroslaw MazurczakSioux Falls$2K
- Mark HuberSioux Falls$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.